Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 18/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.83 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.83 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CSF1R | P07333 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434022 | 0.95 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434005 | 0.93 | FGFR4 (0.87) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15854328 | 0.93 | FGFR4 (0.87) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15412407 | 0.91 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15854331 | 0.89 | FGFR1 (0.87) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15412858 | 0.87 | FGFR1 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434044 | 0.87 | FGFR1 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434009 | 0.87 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434006 | 0.87 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL23314943 | 0.86 | FGFR4 (0.76) | FGFR4FGFR1FGFR2FGFR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-9340514-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340514-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9126951-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126951-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.